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Abstract A cDNA of a processed gene of human DAD-1
(defender against apoptotic cell death) was cloned from the
human neuroblastoma cell line SH-SY5Y. The genomic sequence
of this novel processed gene, DAD-R, lacked introns and was
flanked by 8 bp terminal repeats. RT-PCR showed that the
transcript is expressed predominantly in testis, ovaries, pancreas,
lung and skeletal muscle. DAD-R has several possible initiation
codons, one of them producing an open reading frame comprising
75% of the DAD-1 gene. We determined the chromosomal
localization of DAD-R as 12p11.2^12p12.1, an area linked to
familial synpolydactyly and frequently amplified in a variety of
cancers, including those of testis, ovaries, pancreas and lungs.
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1. Introduction
Defender against apoptotic cell death (DAD-1) was ¢rst
characterized as a ubiquitous protein necessary to prevent
the initiation of the programmed cell death pathway [1]. A
hamster BHK21-derived tsBN7 cell line containing a single
mutation in DAD-1 undergoes apoptosis when shifted into
a non-permissive temperature. Apoptosis under these condi-
tions cannot be prevented by Bcl-2. This integral endoplasmic
reticulum membrane protein, DAD-1, has been shown to be
highly homologous to Ost2p, a yeast component of oligosac-
charyltransferase (OST) complex, which is an enzyme carrying
out the ¢rst step in the N-linked glycosylation pathway of
proteins [2]. Later, the mammalian DAD-1 was con¢rmed
to be a subunit of the mammalian OST complex [3], and
shown to be required for N-glycosylation [4]. However, block-
ing of N-glycosylation with tunicamycin does not trigger
apoptosis in mammalian cells. So eliminating DAD-1 has
been hypothesized to trigger programmed cell death in some
manner that does not arise directly from discontinuation of N-
glycosylation [4]. The report that overexpression of DAD-1 in
Caenorhabditis elegans suppresses developmentally regulated
programmed cell death supports the view of DAD-1 as a
suppressor of apoptosis [5].
Recently, transgenic mice overexpressing DAD-1 in the thy-
mus and the peripheral immune system have been generated.
While apoptosis of thymocytes remains una¡ected, peripheral
T-cells of these mice displayed hyperproliferation [6]. Another
study prepared mice lacking the functional DAD-1 gene by
gene targeting. Homozygous mutants died in utero displaying
apoptotic features [7]. However, the OST activity was appar-
ently retained even after the DAD-1-de¢cient cells were des-
tined to die. Interestingly, heterozygous mice displayed mild
thymic hypoplasia and soft tissue syndactyly [7]. These in vivo
studies demonstrate the role of DAD-1 in the regulation of
cell proliferation and apoptosis. One outcome of the disrup-
tion of developmentally regulated apoptosis is the syndactyly
phenotype, a lack of separation of digits. A recent paper has
mapped a translocation between chromosomes 12 and 22 in
genomic samples of patients with a complex type of synpoly-
dactyly [8].
Our group considered DAD-1 as one potential regulator for
neuronal apoptosis. As a part of the work, we used PCR to
sequence DAD-1-related sequences from neuroblastoma cell
lines. As an embryonic malignancy of the sympathetic nervous
system, neuroblastoma is a useful model for approaching neu-
ronal apoptosis, especially since it has been proposed that a
spontaneous regression of a certain form of neuroblastoma
may involve programmed cell death [9]. We now report the
cloning, initial characterization and chromosomal mapping of
a human processed gene highly homologous to DAD-1. Pro-
cessed genes are a result of reverse transcription of mRNA
and subsequent integration into a genomic site di¡erent from
that of the original gene. Consequently, they typically lack
introns, possess direct repeats at either end and display muta-
tions resulting in new start codons and a stop codon. Most of
such genes are not expressed.
2. Materials and methods
2.1. Cloning and sequencing of DAD-R
For the PCR ampli¢cation of DAD-1, a related human sequence
RNA from the human neuroblastoma cell line SH-5YSY was reverse-
transcribed and ampli¢ed using 50 pmol DAD-1 primers published
previously [10] : 5P-ATGTCGGCGTCGGTAGT-3P and 5P-TCAGC-
CAACGAAGTTCAT-3P. PCR products were cloned into pGEM-T
Vector System I (Promega) and sequenced. The full-length DAD-R
cDNA sequence was then cloned using the 5P- and 3P-RACE tech-
nique (Marathon-Ready cDNA, Clontech) with DAD-R-speci¢c
primers DR1: 5P-AGTGTCAGGCACCCG-3P and DR2: 5P-GTG-
CTAGCAAAGAGAAAG-3P. The same primers and pGEM-T vector
were used to sequence the human genomic sequence of DAD-R em-
ploying the RACE technique (GenomeWalker, Clontech).
0014-5793 / 00 / $20.00 ß 2000 Federation of European Biochemical Societies. All rights reserved.
PII: S 0 0 1 4 - 5 7 9 3 ( 0 0 ) 0 1 3 5 8 - 2
*Corresponding author. Fax: (358)-9-191 59 366.
E-mail: tpkuitti@operoni.helsinki.¢
FEBS 23496 8-5-00
FEBS 23496 FEBS Letters 473 (2000) 233^236
2.2. Chromosomal localization of the human DAD-R processed gene
The DAD-R gene was mapped by £uorescence in situ hybridization
(FISH). A P1 clone used as a probe for FISH was obtained from
Genome Systems Inc. For FISH, human peripheral blood lympho-
cytes were cultured according to standard protocols and cells were
treated with 5-bromodeoxyuridine (BrdU) at early replicating phase
to induce a banding pattern as described earlier [11,12]. An approx-
imately 100 kb probe speci¢c for the human DAD-R gene was labeled
with biotin-11-dUTP (Sigma Chemicals) according to standard pro-
tocols (Nick Translation Kit, BRL). The FISH procedure was carried
out in 50% formamide, 10% dextran sulfate in 2USSC and the signals
were detected according to conventional detection methods as de-
scribed earlier [13,14]. A multicolor image analysis was used for ac-
quisition, display and quanti¢cation of hybridization signals of meta-
phase chromosomes with a system described earlier [15]. To determine
the assignment of the human DAD-R gene a speci¢c probe was hy-
bridized on metaphase chromosomes derived from normal human
lymphocyte cell culture. The identi¢cation of the chromosomes was
based on the DAPI banding pattern, which resembles G-bands after
BrdU incorporation at the early replicating phase. Only double spot
signals were taken into account as speci¢c hybridization signals.
2.3. Semiquantitative RT-PCR
Total RNA of human tissues was obtained from Clontech and total
RNA of neuroblastoma cell lines was extracted using the RNeasy Kit
(Qiagen) according to the manufacturer’s instructions. Reactions for
¢rst strand cDNA synthesis were carried out using 1.0 Wg of total
RNA in a total volume of 20 Wl containing 150 ng random hexamer
primers (Gibco BRL), 0.5 mM dNTPs (Gibco BRL), 10 mM dithio-
threitol, 200 U SuperScriptII Reverse Transcriptase (RT) (Gibco
BRL) and 2 U RNase H (Gibco BRL) in the reaction bu¡er consist-
ing of 20 mM Tris^HCl (pH 8.4), 50 mM KCl, 2.5 mM MgCl2.
Initially the total RNA was denatured at 70‡C for 10 min and imme-
diately chilled on ice. First strand cDNAs were obtained after 10 min
at 23‡C and 50 min at 42‡C. The reaction was terminated at 70‡C for
15 min. RNase H (2 U, Gibco BRL) was added to each RT reaction
followed by incubation at 37‡C for 20 min.
PCR was carried out in a ¢nal volume of 10 Wl containing 0.5 U
Taq Gold polymerase, 200 WM dNTPs, 0.4 WM of each primer, in a
bu¡er consisting of 50 mM KCl, 10 mM Tris^HCl (pH 8.3), 2.0 mM
MgCl2 and 1 Wl of the RT product (reverse-transcribed total RNA).
Speci¢c PCR primers for DAD-R and human DAD-1 had the follow-
ing sequences: for DAD-R: DR3 5P-GAA CAA AGT GGA CTT
CGA AAG C-3P and DR4 5P-GCC AAC AAA GTT CAT GAC
GAT A-3P ; for human DAD-1: 5P-ATG TCG GCG TCG GTA
GT-3P and 5P-TCA GCC AAC GAA GTT CAT-3P. The expected
PCR product sizes were 300 and 342 bp, respectively. All PCR prim-
ers were biotinylated at their 5P ends. PCR samples were overlaid with
mineral oil and ampli¢cation was performed on a PTC-100 Program-
mable Thermal Controller (MJ Research). The samples were dena-
tured initially at 95‡C for 12 min, followed by 20 cycles with dena-
turation at 95‡C for 30 s, annealing at 55‡C for 30 s and extension at
72‡C for 90 s. The ¢nal cycle was followed by a 5 min extension step
at 72‡C. The absence of contaminants was routinely checked by RT-
PCR assays of negative control samples (H2O control or no RT
added). The housekeeping gene GAPD was coampli¢ed as an internal
standard control as previously described (Eggert et al., submitted to
BioTechniques).
Each PCR sample (10 Wl+2 Wl Ficoll Dye Reagent) was analyzed in
parallel with a biotinylated molecular weight marker (Amersham) on
a non-denaturing 6% polyacrylamide gel. DNA was electrotransferred
to a nylon membrane (Hybond N, Amersham) and immobilized by
UV crosslinking. Detection of biotin-labeled DNA was performed
according to the ‘Southern-Light protocol’ (Tropix). Quanti¢cation
of RNA transcript expression was performed by densitometric analy-
sis on X-ray ¢lms using Scion Image 1.55 software. A modi¢cation of
the GAPD primers (biotinylated: non-biotinylated at a ratio of 1:49)
allowed accurate quanti¢cation within the linear range of detection of
both the target transcript and GAPD. The expression of the target
C
Fig. 1. Sequence analysis. A: Comparison of the human genomic se-
quence of DAD-R (top) with the cDNA of DAD-1 (bottom). The
start of the 5P-UTR and the poly(A) tail in the DAD-R cDNA
have been marked by arrowheads. The £anking 8 bp direct repeats
are boxed. The initiation and termination codons of DAD-1 and
putative initiation and termination codons of DAD-R are shown in
bold. B: Amino acid sequence comparison of putative DAD-R and
DAD-1 (translation frame of the DAD-R processed gene starting at
nt 100). Thirteen amino acid substitutions are shown with asterisks.
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transcript was normalized by taking the ratio between the densitomet-
ric unit of the transcript and that of the internal control, GAPD.
3. Results and discussion
Processed genes that are expressed as mRNA are sometimes
called retrogenes [16]. We decided to call our novel processed
gene DAD-R to make a distinction with other DAD-1-related
genes, of which DAD-2 has been recently cloned from Arabi-
dopsis thaliana (GenBank accession number AF030172). Some
reported processed genes that are expressed at the mRNA
level also retain the functionality of the ‘parental gene’. The
two best known examples in humans, PGK2 and PDHA2, are
expressed only during spermatogenesis and were derived from
X-linked genes [17,18]. These genes are expressed exclusively
in the testis and they have retained the full-length open read-
ing frame (ORF) of their parental genes. For these reasons,
we decided to study the structure of DAD-R mRNA and its
expression in several tissues. Since we discovered a novel,
DAD-1-related gene, and since DAD-1 itself has been mapped
to chromosome 14, we decided to map the novel gene.
DAD-R genomic gene has several common characteristics
of a retrogene: lack of introns; direct 8 nt long repeats; nu-
cleotide sequence homology to DAD-1 both within and out-
side the translated region; and novel start and stop codons
(Fig. 1A). There are several possible initiation codons in
DAD-R mRNA, one of which matches relatively well with
the Kozak consensus sequence for mammalian protein biosyn-
thesis and is followed by an ORF corresponding to 75% of the
DAD-1 ORF (Fig. 1B).
We found expression of DAD-R mRNA in several organs.
Strongest expression was seen in lung, ovaries, testis and small
intestine (Fig. 2A). Pancreas, skeletal muscle, spleen, placenta
and thymus also showed some expression. The RT-PCR re-
action was performed twice independently, resulting in iden-
tical expression patterns. Expression of a human processed
gene in several organs has not been reported before, though
there are several reports on human processed genes having
single organ expression. To ensure that the PCR products
seen in the RT-PCR panels were derived from DAD-R
cDNA, each product was cut with the restriction enzyme
Fig. 2. Expression of DAD-R in various human tissues tested by
RT-PCR. Reverse-transcribed RNA was ampli¢ed by PCR with
primers DR3 and DR4 (see Section 2). A: DAD-R (D) in human
organs. RNA control (no RT, testis) (lane 1), pancreas (2), adrenal
gland (3), thymus (4), brain (5), skeletal muscle (6), small intestine
(7), spleen (8), placenta (9), testis (10), liver (11), kidney (12), ovary
(13), lung (14). M: molecular weight markers. GAPDH (G) was
used as an internal control for RNA quanti¢cation in all RT-PCR
reactions. B: DAD-R (D) in human neuroblastoma cell lines. NBL-
wN (lane 1), CHP903 (2), CHP901 (3), KAN (4), NLF (5), NGP
(6), KCNR (7), IMA5 (8), CHP 134 (9), NBL-S (10), SK-N-AS
(11), LAN6 (12), NB69 (13), SY5Y (14). M: molecular weight
markers. GAPDH (G) was used as an internal control for RNA
quanti¢cation in all RT-PCR reactions.
Fig. 3. Chromosomal localization of DAD-R. A: Grayscale image of partial metaphase spread showing speci¢c hybridization signals on chro-
mosomes 12. A grayscale image (B) and an ideogram (C) of chromosome 12 demonstrating the speci¢c assignment of the human DAD-R gene
on band 12p11.2^12.1.
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PstI, which cuts DAD-R but not DAD-1. This resulted in the
disappearance of the 300 bp PCR product from the RT-PCR
panel. Conversely, treatment with the restriction enzyme AvaI,
which cuts DAD-1 but not DAD-R, had no e¡ect on the 300
bp bands in the panel.
A panel of 14 neuroblastoma cell lines revealed DAD-R
mRNA expression in 10 of them (Fig. 2B). We will follow
this by expanded expression studies of primary neuroblastoma
tumors and a wider selection of neuroblastoma cell lines.
Most processed genes are transcriptionally inactive and
contain a number of mutations that render them non-func-
tional. However, there are some functional processed genes.
As mentioned previously, PGK2 and PDHA2 are expressed
only during spermatogenesis and were formed from X-linked
genes [17,18]. Atypically, though DAD-R is expressed in sev-
eral organs, it contains mutations truncating the length of the
ORF of the original gene, and the parental gene, DAD-1, is
not X-linked. Apparently DAD-R is not expressed at high
levels. Whether possible translation products have any biolog-
ical activity remains to be determined.
Human DAD-R gene hybridizations showed speci¢c hy-
bridization signals on chromosome 12p11.2^12p12.1 (Fig. 3).
It is interesting to note that DAD-R is localized at 12p11.2^
p12.1, an area ampli¢ed in several human tumors. Recent
data suggest that there are more than one putative oncogenes
in the vicinity of this area [19]. DAD-R is expressed predom-
inantly in testis, ovaries, pancreas, lung and skeletal muscle;
high level gains of 12p or 12p12 have been characterized in
tumors associated with testicular germ cell tumors (GCT),
ovarian GCTs, pancreatic cancer and lung adenocarcinoma
[20]. Gains have also been reported in other tumors, such as
gliomas [21] and secondary myeloid leukemia [22]. The highest
prevalence of 12p12 ampli¢cations has been reported in tes-
ticular GCTs, 80% of which display a high copy number of
12p or 12p12 regions. Our FISH mapping places DAD-R at
12p11.2^p12.1. CGH results from secondary myeloid leuke-
mia implicate a small amplicon localized in the 12p11.2^p12
subregion. A recent study was able to determine a 300 kb long
shortest region of ampli¢cation common to all GCTs [23].
A paper describing the chromosomal translocation cloned
from patients with familial synpolydactyly pinpointed two re-
gions involved in the event: 12p11.3 and 22q13.3 [8]. Thus,
12p11.2^p12.1, where DAD-R is located, seems to be a region
linked to both synpolydactyly and chromosomal ampli¢cation
associated with certain neoplasms ^ a common feature of both
being the control of cell proliferation. In vivo studies on the
DAD-1 gene, mapped to chromosome 14, clearly demonstrate
that DAD-1 is involved in the regulation of apoptosis and cell
proliferation in certain tissues [6,7]. Surprisingly, DAD-1 het-
erozygous mice have the polydactyly phenotype. This poses an
interesting dilemma about the possible biological activity of
DAD-R and indicates that it could be a candidate gene for
these pathologies.
Presumably the predicted oncogene or oncogenes residing
at 12p12 confer on certain neoplasms some type of advantage
that led to the ampli¢cation of this chromosomal region.
Based on ubiquitous ampli¢cation of several 12p bands in
testicular GCT samples it has been hypothesized that more
than one gene contributing to oncogenesis may be located
within the 12p area [19]. Our work on tumor sample Southern
blots shows rearrangement of DAD-R in some samples; we
are currently expanding these studies and investigating ele-
vated expression levels of DAD-R in certain tumor samples
(Kuittinen et al., in preparation). Our low cycle number PCR
gives an accurate comparison of mRNA copy numbers and
DAD-R expression in tumor samples is higher than the organ
expression. In light of the reported role of DAD-1 in the
regulation of apoptosis, the multiple organ expression of its
processed gene DAD-R and the chromosomal localization of
the latter, the possibility of some type of biological activity of
DAD-R should be investigated further.
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